Triprolidine

Triprolidine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Triprolidine is a antihistamine that is FDA approved for the treatment of symptoms due to hay fever (allergic rhinitis) or other upper respiratory allergies:

• runny nose
• sneezing
• itching of the nose or throat
• itchy, watery eyes. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Triprolidine FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Triprolidine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Triprolidine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Triprolidine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Triprolidine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Triprolidine in pediatric patients.

Contraindications

There is limited information regarding Triprolidine Contraindications in the drug label.

Warnings

'Do not exceed recommended dosage'

Ask a doctor before use if you have:

• a breathing problem such as emphysema or chronic bronchitis
• glaucoma
• trouble urinating due to an enlarged prostate gland

'Ask a doctor before use if you are taking sedatives or tranquilizers'

When using this product

• excitability may occur, especially in children
• may cause drowsiness
• alcohol, sedatives and tranquilizers may increase the drowsiness effect
• avoid alcoholic beverages
• use caution when driving a motor vehicle or operating machinery

'Stop use and ask a doctor if new symptoms occur' 'If pregnant or breast-feeding, ask a health professional before use.' 'Keep out of the reach of children.' 'In case of overdose, get medical help or contact a Poison Control Center right away.'

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Triprolidine Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Triprolidine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Triprolidine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Triprolidine in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Triprolidine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Triprolidine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Triprolidine in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Triprolidine in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Triprolidine in geriatric settings.

Gender

There is no FDA guidance on the use of Triprolidine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Triprolidine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Triprolidine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Triprolidine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Triprolidine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Triprolidine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Triprolidine Administration in the drug label.

Monitoring

There is limited information regarding Triprolidine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Triprolidine and IV administrations.

Overdosage

There is limited information regarding Triprolidine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Triprolidine Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Triprolidine Mechanism of Action in the drug label.

Structure

There is limited information regarding Triprolidine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Triprolidine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Triprolidine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Triprolidine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Triprolidine Clinical Studies in the drug label.

How Supplied

There is limited information regarding Triprolidine How Supplied in the drug label.

Storage

There is limited information regarding Triprolidine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Triprolidine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Triprolidine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Triprolidine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Triprolidine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Triprolidine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Triprolidine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Triprolidine

Clinical data
Pregnancy category	C (US)
Routes of administration	Oral
ATC code	R06AX07 (WHO)
Legal status
Legal status	OTC (US)
Pharmacokinetic data
Bioavailability	4% oral
Protein binding	90%
Metabolism	Hepatic (CYP2D6)
Elimination half-life	4 to 6 hours
Excretion	Renal
Identifiers
IUPAC name 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl- prop-1-enyl]pyridine
CAS Number	486-12-4
PubChem CID	5282443
DrugBank	APRD00306
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H22N2
Molar mass	278.391 g/mol
3D model (JSmol)	Interactive image
Melting point	60 °C (140 °F)
Solubility in water	500 mg/mL (20 °C)
SMILES CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3

WikiDoc Resources for Triprolidine
Articles
Most recent articles on Triprolidine Most cited articles on Triprolidine Review articles on Triprolidine Articles on Triprolidine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Triprolidine Images of Triprolidine Photos of Triprolidine Podcasts & MP3s on Triprolidine Videos on Triprolidine
Evidence Based Medicine
Cochrane Collaboration on Triprolidine Bandolier on Triprolidine TRIP on Triprolidine
Clinical Trials
Ongoing Trials on Triprolidine at Clinical Trials.gov Trial results on Triprolidine Clinical Trials on Triprolidine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Triprolidine NICE Guidance on Triprolidine NHS PRODIGY Guidance FDA on Triprolidine CDC on Triprolidine
Books
Books on Triprolidine
News
Triprolidine in the news Be alerted to news on Triprolidine News trends on Triprolidine
Commentary
Blogs on Triprolidine
Definitions
Definitions of Triprolidine
Patient Resources / Community
Patient resources on Triprolidine Discussion groups on Triprolidine Patient Handouts on Triprolidine Directions to Hospitals Treating Triprolidine Risk calculators and risk factors for Triprolidine
Healthcare Provider Resources
Symptoms of Triprolidine Causes & Risk Factors for Triprolidine Diagnostic studies for Triprolidine Treatment of Triprolidine
Continuing Medical Education (CME)
CME Programs on Triprolidine
International
Triprolidine en Espanol Triprolidine en Francais
Business
Triprolidine in the Marketplace Patents on Triprolidine
Experimental / Informatics
List of terms related to Triprolidine

Overview

Triprolidine hydrochloride is an over-the-counter antihistamine. It is used to combat the symptoms associated with allergies and is sometimes combined with other cold medications designed to provide general relief for flu-like symptoms. Like many over-the-counter antihistamines, the most common side effect is drowsiness.

Trade names

• Actidil
• Myidil
• Actifed (as a combination with pseudoephedrine) - no longer contains pseudoephedrine or triprolidine as of the end of 2006.

External links

• Information at WholeHealthMD.com